SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare is trending due to a new institutional offering at $5 per share and the termination of its ATM facility, although investor sentiment is sharply divided over news of an unexpected additional Phase 2 study pushing IHL-42X's Phase 3 trial start to late 2027, even as NASDAQ compliance is achieved. While many are furious about prolonged timelines and perceived management actions, others view the institutional backing and ATM termination as stabilizing factors for the biotech's pipeline.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is trending due to its strategic partnership with Palantir and World View to develop AI-enabled multi-domain intelligence and defense systems, a move seen as highly transformative by the community alongside recent defense tech acquisitions. While many investors are bullish on the company's long-term potential and anticipate a short squeeze, others are expressing concerns over share dilution and the stock's struggle to maintain gains.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending as its strong Q4 earnings beat, GAAP profitability, and a new $500 million share buyback are met with mixed investor reactions due to modest forward growth guidance and several analyst price target reductions. The community is actively debating the company's strategic shift to 'Agentic AI' and potential government contracts against concerns about its growth trajectory in a competitive automation market.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is actively discussed following multiple strategic announcements, including a sovereign AI architecture with NVIDIA and expanded partnerships in defense, energy, and commercial AI. The community is highly enthusiastic, viewing these collaborations as strong validation of Palantir's AI platform and its crucial role across diverse, high-stakes sectors.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending after securing pivotal Japanese marketing approval for its Alpha DaRT technology, a massive de-risking event that has analysts raising price targets while the community asserts these valuations are still significantly undervalued given the company's strong cash position and promising oncology pipeline.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the community eagerly awaits its live product demonstrations and Lightwave Award at the upcoming OFC Conference, fueling speculation around new partnerships and substantial orders for its optical interconnect technology, especially following Marvell's optimistic projections for Celestial AI's photonic fabric, which incorporates POET's solutions.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following the successful launch of its Alpha Flight 7 mission, which delivered a Lockheed Martin payload into orbit, marking a crucial comeback for the Alpha rocket program and driving positive community sentiment in the competitive commercial space sector.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is trending after announcing a development agreement with Tower Semiconductor, a major silicon photonics foundry, to integrate its electro-optic polymer modulators. The community views this as a critical validation, believing it could embed LWLG's technology into key supply chains for high-speed AI data centers and accelerate broader industry adoption of its polymer solutions.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is trending due to a rapid price surge that has the community questioning its immediate catalyst, with many speculating on a gamma squeeze and unusual options activity. This momentum is widely attributed to Himax's role as a key supplier for NVIDIA's Co-Packaged Optics (CPO) initiatives, alongside positive movement from its CPO partner FOCI, underscoring its position in the silicon photonics market for AI data centers.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending due to escalating tanker attacks and critical supply disruptions in the Strait of Hormuz, driving strong community debate over whether substantial strategic reserve releases can mitigate the sustained geopolitical risk or if oil prices are poised for further significant volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.2% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 6.2% - Here's What Happened...

<ul class="summary-bullets"><li>The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance treatment for AML patients.</li><li>The readout is nearing a key trigger, with eight more events needed to launch the final analysis in the event-driven study.</li><li>Maxim noted that slower event accumulation in survival trials can sometimes suggest longer patient survival.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) rallied on Monday ahead of a closely watched readout from its late-stage acute myeloid leukemia (AML) trial, even as former hedge fund manager Martin Shkreli said he remains “very bearish” on the stock and expects the drug to fail.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped nearly 8% on Monday to end at 5.96, hitting its highest levels in about four years, and gained another 2% in after-hours trading.&nbsp;<h2 class="st-heading-2">Shkreli Stays Bearish On Sellas</h2>Shkreli,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2031050836869321156">responding on X</a> to a user who asked whether he was still bearish on Sellas, said: "Very bearish, it will fail." In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/2031061009826459892">separate&nbsp;</a>post, he said that the company has no clear mechanism of action and lacks strong clinical data.The comments come as Sellas moves closer to a potentially market-moving update from its Phase 3 Regal study evaluating Galinpepimut-S, or GPS, in AML.Shkreli’s latest comments build on a skeptical view he had already expressed in 2024, when he published a long&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=IWpmc9OepVw">video discussion</a> analyzing Sellas and its Regal trial. In the review, he questioned the trial design, the patient population and the statistical hurdles the study would need to clear.He argued that the trial was being run in a difficult AML setting, with patients in second complete remission after relapse, and said the study’s sample size of about 127 patients could leave little room for error. He also suggested that showing a meaningful overall survival benefit in that population could be difficult.His fresh comments are notable as they come just months after he publicly walked back another high-profile bearish biotech call. In December, after Capricor Therapeutics posted&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-calls-his-capricor-therapeutics-short-a-bad-call-after-dmd-trial-delivers-surprise-win/cLIXyn6RE1y">positive Hope-3 data</a>, Shkreli acknowledged that it had been “a bad call” and apologized to followers who acted on his short thesis.<h2 class="st-heading-2">Regal AML Readout Nears</h2>Investor focus is now centered on the timing of the Regal readout. Sellas said in late December that the contract research organization overseeing the Phase 3 trial had recorded 72 events as of Dec. 26, 2025. The study needs 80 events to trigger the final analysis, meaning it was eight events short of that threshold at the time of the company’s last update.The trial is testing GPS as a maintenance treatment for AML patients whose disease had returned but later went back into remission after additional therapy. The main goal is to determine whether the drug improves overall survival.Since the study is event-driven, the company has not given a fixed date for the readout. Instead, the timeline depends on when the 80th event occurs. Once that threshold is reached, the study will be unblinded and analyzed.&nbsp;That timeline has kept investors focused on the stock since late last year. Sellas shares surged more than 100% during December alone as traders positioned ahead of the potential catalyst.<h2 class="st-heading-2">Sellas CEO Backs GPS Strategy</h2>Over the weekend, Sellas CEO Angelos Stergiou said that GPS&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-falls-premarket-investors-cautious-as-aml-trial-readout-nears/cZdVgoyRIId">will target</a> leukemia regardless of genetic mutations. He said the therapy targets the Wilms Tumor-1 (WT1) antigen and is designed to activate multiple types of T cells, so the immune system can attack leukemic stem cells and remaining cancer cells.Meanwhile, Maxim noted that in survival-driven trials, a slower buildup of events can sometimes&nbsp;indicate longer patient survival.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS shifted to ‘extremely bullish’ from the ‘bullish’ zone over the past day amid a 580% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_10851125ea.webp" alt="sls ss.png" width="968" height="146"><figcaption>SLS sentiment and message volume as of March 9 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/SunnySeed/message/647067207">called</a> SLS the “Most organic growth biotech stock in the history of biotech stocks!!”<stembedurl>https://stocktwits.com/SunnySeed/message/647067207</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/stjernerogvann/message/647066268">pushed back</a> on Shkreli’s stance, saying “his primary arguments were extremely flawed,” while noting the stock has risen sharply since he previously criticized it when it traded near $1.<stembedurl>https://stocktwits.com/stjernerogvann/message/647066268</stembedurl>SLS stock has skyrocketed 400% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Former pharmaceutical executive Martin Shkreli points as he exits the courthouse after the jury issued a verdict in his case at the U.S. District Court, August 4, 2017 in the Brooklyn borough of New York City. (Photo by Drew Angerer/Getty Images)

SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail

Shkreli argued that the company lacks a clear mechanism of action and strong clinical data.

Equity

<ul class="summary-bullets"><li>On Monday, Wall Street staged a sharp rebound amid volatile oil prices and developments related to the Iran war.</li><li>Semiconductor stocks led the rebound, with Broadcom, Micron, AMD and Nvidia posting strong gains.</li><li>Investors await key catalysts, including NFIB data, existing home sales, and earnings from Oracle and Adobe.</li></ul>U.S. stock futures traded lower late Monday after a dramatic rebound on Wall Street, as traders weighed fresh developments in the Iran conflict and wild swings in oil prices.As of 8.33 p.m. ET, Nasdaq 100 and S&amp;P 500 futures were down about 0.4%, while Dow futures were down 0.3%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> was ‘bearish’ amid ‘high’ message volume, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘neutral’ amid ‘high’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>Markets reacted to ongoing geopolitical developments after U.S. President Donald Trump suggested the war with Iran could be nearing its end, even as investors weighed the economic fallout from sharp swings in oil prices.In the prior session, major indexes closed higher after staging a sharp rebound from intraday losses:<figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>0.50%</td><td>47,740.80</td></tr><tr><td>S&amp;P 500</td><td>0.83%</td><td>6,795.99</td></tr><tr><td>Nasdaq Composite</td><td>1.38%</td><td>22,695.95</td></tr></tbody></table></figure>Sentiment improved after Trump told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/live-updates/us-iran-war-israel-stock-prices-down-oil-prices-up-despite-trump-reassurance/">CBS News</a> that the war was “very complete, pretty much,” adding that military operations were “very far” ahead of the previously expected four- to five-week timeline. The president also said ships were moving through the Strait of Hormuz and that he was “thinking about” taking control of the key shipping passage.Oil markets experienced dramatic swings throughout the session. West Texas Intermediate crude briefly surged above $119 per barrel overnight amid fears that disruptions around the Strait of Hormuz could choke off global supply, before tumbling toward the low $80s after Trump’s comments eased some geopolitical concerns. Brent crude also pulled back to around $84 a barrel.By the end of the day, crude prices retreated sharply as traders weighed the outcome of a virtual meeting on Tuesday with energy ministers from the Group of Seven nations, including the U.S., Canada, France, Germany, Italy, Japan and the United Kingdom, to discuss potentially releasing strategic oil reserves.Technology stocks also helped drive the late-session rebound. Semiconductor shares led gains, with Broadcom, while Micron Technology and Advanced Micro Devices climbing roughly 5% each. Nvidia rose nearly 3%.The dramatic turnaround marked the scale of intraday volatility in equity markets. The Kobeissi Letter&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/KobeissiLetter/status/2031133637274411314">said on X</a> that&nbsp;certain S&amp;P 500 options&nbsp;surged more than 24,000% within minutes after Trump’s remarks,&nbsp;and investors were “witnessing historic volatility.”<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>Zevra Therapeutics (ZVRA): Shares jumped 17% in after-hours trading after the company reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zvra-stock-soars-on-upbeat-q4-results/cZdnbfHRIeO">fourth-quarter</a> revenue of $34.1 million, beating analyst estimates of $28.05 million, driven largely by sales of its Niemann-Pick disease treatment MIPLYFFA.Sellas Life Sciences (SLS): The stock rose 2% in extended trading as investors await the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-falls-premarket-investors-cautious-as-aml-trial-readout-nears/cZdVgoyRIId">final readout</a> from its late-stage AML trial, while CEO Angelos Stergiou highlighted that the company’s GPS immunotherapy will target leukemia regardless of genetic mutations.Relmada Therapeutics (RLMD): Shares fell 4% after-hours after the company announced a $160 million private investment in public equity financing and provided updates on its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-rlmd-stock-soaring-today/cZdVSq1RIIW">Phase 2 trial</a> of bladder cancer treatment NDV-01.United States Oil Fund (USO): The oil ETF gained 2% in extended trading as crude markets remained volatile following Trump’s comments suggesting the Iran conflict could be nearing an end.Casey’s General Stores (CASY): Shares slipped 2% after-hours on reporting quarterly results with revenue missing estimates, even as it beat earnings expectations and raised its fiscal 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) growth outlook.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>In broader markets, the yield on the benchmark 10-year U.S. Treasury note was around 4.13%, little changed after rising as high as 4.21% earlier in Monday’s session. Gold traded near $5,135 an ounce.Asian markets opened higher on Tuesday. The MSCI's broadest index outside Japan rose about 0.7%, with stocks in Australia and Japan posting gains.&nbsp;Among the catalysts for the day are the NFIB Small Business Optimism Index for February and existing home sales data. Earnings from Oracle are due Tuesday, and Adobe is scheduled to report Thursday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 U.S. President Donald J. Trump sits at a table monitoring military operations during Operation Epic Fury against Iran. (Photo by The White House via X Account/Anadolu via Getty Images)

Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours

Oil whipsawed, with WTI briefly topping $119 before plunging toward the low $80s as Trump said the Iran war could end soon.

Why US Stock Futures Are Slipping After Sharp Wall Street Rebound

SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High - Here's What Happened...

<ul class="summary-bullets"><li>CEO Angelos Stergiou said the company’s lead immunotherapy Galinpepimut-S (GPS), will attack leukemia cells regardless of genetic mutations.</li><li>The therapy targets the Wilms Tumor-1 (WT1) antigen, thereby activating multiple T cells to eliminate leukemic stem cells and small residual cancer cells.</li><li>Investors are closely watching the Phase 3 Regal trial, where final analysis will begin after 80 survival events.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS)&nbsp;fell 1.5% in premarket trading on Monday as investors await a key readout from its late-stage leukemia study, while the company’s CEO said its GPS immunotherapy can attack cancer cells regardless of genetic mutations.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped nearly 5% on Friday to hit $5.53 and added another 0.3% in extended trading.<h2 class="st-heading-2">Inside Sellas’ GPS Immunotherapy Approach</h2>CEO Angelos Stergiou said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7435690855652495360/">LinkedIn post</a> over the weekend that Sellas’ lead immunotherapy Galinpepimut-S (GPS) is designed to target leukemia regardless of genetic mutations.Stergiou said GPS targets the Wilms Tumor-1 (WT1) antigen, a protein commonly expressed on leukemia cells, and is designed to activate multiple types of T cells, enabling the immune system to attack both leukemic stem cells and any remaining traces of cancer, regardless of the tumor’s genetic mutations.“Targeted therapies are great, but they are inherently vulnerable to mutational evolution,” Stergiou said, adding that Sellas is developing a “security force” approach in which immunotherapy trains the immune system to recognize and eliminate cancer cells even as they change.Stergiou also highlighted SLS009, a drug designed to block CDK9, a protein that helps cancer cells survive by supporting other growth-related proteins such as MCL-1 and MYC.<h2 class="st-heading-2">Phase 3 AML Trial Nears Final Analysis</h2>Investor focus has centered on Sellas’ late-stage Regal trial, which is testing GPS as a maintenance treatment for patients with acute myeloid leukemia (AML), whose disease returned but later went back into remission after additional therapy.The event-driven trial will assess whether GPS can improve overall survival. The final analysis will begin once 80 survival events are recorded. Sellas previously said the contract research organization monitoring the study had logged 72 events as of Dec. 26, bringing the trial closer to the threshold needed to trigger the final readout.Maxim said that slower accumulation of events in survival-driven trials can sometimes reflect longer patient survival, although the study remains blinded until the data are formally analyzed.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘bullish’ amid a 68% jump in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_7b76c4ef6d.webp" alt="sls ss.png" width="965" height="142"><figcaption>SLS sentiment and message volume as of March 9 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Harsh1210/message/646961981">expects</a> the stock to “drop today cause of how the market is going to be. Shorts will win cause of that.”<stembedurl>https://stocktwits.com/Harsh1210/message/646961981</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Newbie202/message/646961707">said</a>, “REGAL Phase 3 &amp; SLS009 advancing — Two AML shots on goal — a lifeline for patients, hope for families, and upside for investors.”<stembedurl>https://stocktwits.com/Newbie202/message/646961707</stembedurl>SLS stock has surged over 360% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has surged over 360% over the past year. (Photo credit: Getty Images)

SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout

The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.

<ul class="summary-bullets"><li>Investors are monitoring the Miami Cancer Institute Immunotherapies Summit, where Sellas' scientific advisor, Guenther Koehne, is set to deliver opening remarks.</li><li>The Phase 3 Regal trial evaluating GPS in acute myeloid leukemia has recorded 72 of the 80 survival events needed to trigger the final analysis.</li><li>Maxim noted that delays in event-driven trials can sometimes reflect longer patient survival.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) snapped a five-session winning streak on Thursday after a massive rally, as traders eyed a leukemia immunotherapy summit featuring a company advisor for potential clues ahead of the upcoming Phase 3 trial readout.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> ended nearly 5% lower at $5.28 on Thursday.&nbsp;The stock has rallied sharply in recent months, soaring nearly 330% over the past year and gaining more than 100% in December alone as investors positioned themselves ahead of a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-red-hot-streak-short-bets-retail-big-pharma-buyout/cZdQmWKRIdM">key catalyst</a> tied to the company’s late-stage acute myeloid leukemia program.<h2 class="st-heading-2">AML Immunotherapy Summit In Focus</h2>Investors are now looking ahead to the Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies, a two-day conference focused on emerging immunotherapy approaches for blood cancers.The conference is set to open Friday morning with welcome remarks from Guenther Koehne, deputy director and chief of blood and marrow transplant and hematologic oncology at the Miami Cancer Institute. Koehne also serves on Sellas Life Sciences' scientific advisory board and has been involved in research related to the company’s immunotherapy programs.<h2 class="st-heading-2">Sellas GPS Program Gains Spotlight</h2>Last week, Koehne&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7432479850604601345/?originTrackingId=BJyglAlEFdTqi7a%2F70hu5Q%3D%3D">said on LinkedIn</a> that&nbsp; targeting Wilms’ tumor 1 (WT1), a protein commonly found in leukemia cells, will “remain important.” He noted that patients whose tests still showed WT1 signals before or after stem cell transplants tended to have worse outcomes, highlighting the need for therapies that strengthen immune responses against WT1.The comments came shortly after a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7432465771852636161/">LinkedIn exchange</a> with Sellas CEO Angelos Stergiou, in which the two discussed the company’s lead immunotherapy candidate, Galinpepimut-S (GPS), and possible future indications once results from the Phase 3 Regal trial become available.Stergiou said they reviewed the GPS program and the broader potential of WT1-targeted treatments across multiple cancers, signaling the therapy may help the body mount a broader attack against cancer cells.<h2 class="st-heading-2">Phase 3 AML Trial Nears Key Trigger</h2>Investor interest in Sellas has been centered on the Phase 3 Regal trial, which is evaluating GPS as a maintenance treatment for patients with acute myeloid leukemia (AML) whose cancer returned but later went back into remission after additional therapy.The trial will determine whether the immunotherapy can extend overall survival. Since the study is event-driven, the final analysis will be triggered once 80 survival events occur. Sellas said the contract research organization overseeing the trial had recorded 72 events as of Dec. 26, bringing the study close to the threshold needed to begin the final analysis.Maxim noted that delays in reaching the event trigger can sometimes indicate longer patient survival, though the results remain blinded until the study is unblinded and analyzed.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_30f72cdcad.webp" alt="sls ss.png" width="969" height="143"><figcaption>SLS sentiment and message volume as of March 6 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/67X_ROI_Q1_2026/message/646767811">said</a>, “Every SLS investor is guaranteed huge ROI when the Gps Phase 3 Results are announced.”<stembedurl>https://stocktwits.com/67X_ROI_Q1_2026/message/646767811</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Slstothamoon/message/646765855">noted</a> Koehne's welcome speech at the leukemia summit and raised speculation about whether the company or its therapies could be mentioned.<stembedurl>https://stocktwits.com/Slstothamoon/message/646765855</stembedurl>SLS stock has declined 5% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout

The stock's recent surge has been driven by anticipation around the late-stage Regal trial evaluating its leukemia therapy Galinpepimut-S (GPS).

<ul class="summary-bullets"><li>The stock finished higher in 12 of the past 13 sessions as investors positioned ahead of key AML trial data.</li><li>Quiver Quantitative data shows that about 40% of recent institutional activity involves new purchases.</li><li>Retail investors are speculating that positive Regal data could attract interest from big pharma companies in a potential buyout.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped to a four-year high on Wednesday as investors positioned ahead of a key clinical catalyst, even as short sellers have stepped up their bets against the rally.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> rose over 4% on Wednesday to $5.54, and has finished higher in 12 of the past 13 trading sessions, reflecting growing anticipation around the company’s late-stage acute myeloid leukemia (AML) therapy.<h2 class="st-heading-2">Short Sellers Build Positions On SLS Rally</h2>The buildup began after the Regal Phase 3 trial update in late December, when the company said the contract research organization managing the study had recorded 72 events as of Dec.26, bringing the trial closer to the 80-event threshold required to trigger final analysis. At that time, short interest was around 23.4% between Dec. 15 and Dec. 31.Short positioning continued to climb into early January, reaching about 28.4% between Jan. 1 and Jan. 15, as investors positioned ahead of the expected data readout.The rise accelerated after Jan. 14, when the company announced a collaboration with the Impact-AML European research network to evaluate SLS009, its selective CDK9 inhibitor, across clinical sites in Europe. Following the deal, short interest peaked at around 29% between Jan.16 and Jan.29, marking the highest level in a year.Overall, short bets have increased about 15% since the December Regal update, even as the stock has more than doubled during the month.Since the Regal trial is event-driven, the timing of the final readout depends on the time of the 80th event. Maxim noted that in survival-based studies, delays in reaching the trigger can sometimes indicate longer survival among patients, though the results remain blinded until the final readout.<h2 class="st-heading-2">Institutions Quietly Accumulate SLS</h2>Despite rising short interest, institutional investors appear to be accumulating shares. Data from Quiver Quantitative shows that about 40% of recently tracked institutional activity involved new purchases, while roughly 75% of activity overall consisted of funds either buying, increasing, or holding positions in the stock.SLS stock has skyrocketed 370% over the past year, far outperforming the U.S. benchmark indexes.<img src="https://news.stocktwits-cdn.com/sls_koyfin_png_411648ff83.webp" alt="sls koyfin.png">Large asset managers, including Vanguard Group, BlackRock, and State Street, are among the company’s largest institutional holders.<h2 class="st-heading-2">Retail Bets On Big Pharma Deal</h2>The stock’s sharp rally has fueled speculation among retail traders that the company could become a takeover target if its Regal trial succeeds. On Stocktwits, retail sentiment for SLS has remained ‘extremely bullish’ over the past month amid a 116% surge in message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_2c2d754ca3.webp" alt="sls ss.png" width="967" height="142"><figcaption>SLS sentiment and message volume as of March 5 | Source: Stocktwits</figcaption></figure>One trader&nbsp;<a href="https://stocktwits.com/yG19/message/646644784">said</a> that the company’s technology and trial progress could lead to a “strategic acquisition,” while another&nbsp;<a href="https://stocktwits.com/SellasgpsDormantBAT9/message/646642205">suggested</a> that partnerships with European research networks used by major drugmakers such as Pfizer and AbbVie could attract interest from large pharmaceutical companies.<stembedurl>https://stocktwits.com/yG19/message/646644784</stembedurl>Some users also&nbsp;<a href="https://stocktwits.com/Cresskill198/message/646635403">noted</a> the large short position, suggesting the setup resembles a “game of chicken” between bullish investors and short sellers ahead of potential trial updates.<stembedurl>https://stocktwits.com/Cresskill198/message/646635403</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/SellasgpsDormantBAT9/message/646642860">said</a>, “With New FDA Commissioner Marty Makary, both GPS and SLS009 qualify for National Priority Voucher (CNPV) pilot program. Delay is because Co. is being BO, Big pharmaceutical Buyer will conduct all future clinical trials.”For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has skyrocketed 370% over the past year, far outperforming the U.S. benchmark indexes. (Photo credit: Getty Images)

SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout

Short interest has risen about 15% since the December update on the Phase 3 Regal trial.

<ul class="summary-bullets"><li>The event-driven study had 72 events recorded as of Dec. 26, 2025, nearing the 80 events required to trigger the final survival analysis.</li><li>Maxim said that although top-line data had been expected by the end of 2025, delays in reaching the event threshold in survival-based trials may reflect longer patient survival.</li><li>Koyfin consensus shows an average price target of $6.83, implying about 29% potential gains from current levels.&nbsp;</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) jumped to over a three-year high on Monday as investors await the final readout of its late-stage acute myeloid leukemia (AML) therapy, with analysts signaling the delayed event timing could indicate stronger survival outcomes.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has finished in the green in 11 of the last 12 sessions, gaining more than 5% on Tuesday to close at $5.31.<h2 class="st-heading-2">Phase 3 AML Trial Nears Key Event Trigger</h2>The rally comes as the company’s Phase 3 Regal study evaluating Galinpepimut-S (GPS) in AML approaches the event threshold required to trigger the final analysis. The stock has surged ahead of the potential data catalyst, gaining more than 100% during December alone.Sellas said in late December that the contract research organization overseeing the Regal trial reported 72 events as of Dec. 26, 2025, placing the study close to the 80 events required to initiate the final analysis.&nbsp;The trial is testing GPS as a maintenance treatment for AML patients whose cancer returned but went back into remission after additional therapy. The study’s main goal is to see whether the drug helps patients live longer.Since the trial is event-driven, the timing of the final readout depends on the time of the 80th event. The company said it will announce the milestone once it is reached. Sellas also noted that it remains fully blinded to the efficacy and survival outcomes.Once the 80-event threshold is reached, the study will be unblinded and analyzed to determine whether the therapy improves survival outcomes for AML patients.<h2 class="st-heading-2">Analysts See Delay As Potentially Positive Signal</h2>After the December update on the Regal trial by Sellas, Maxim said that “in any clinical trial, pinpointing the timing of events and survival timelines is challenging.”The brokerage said that while top-line data had been expected by the end of 2025, delays in event-driven studies like Regal can sometimes indicate longer survival among patients, though the firm noted the results remain fully blinded and it is too early to draw conclusions.<h2 class="st-heading-2">Wall Street Sees Further Upside</h2>Despite the recent rally, analysts still see additional upside potential. According to Koyfin consensus estimates, the stock carries an average 12-month price target of $6.83, implying a 29% upside from current levels.&nbsp;Analyst sentiment remains positive, with one 'Buy' rating and two 'Hold' ratings among covering analysts, while the average analyst rating stands at 'Strong Buy' on a five-point scale.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for SLS was ‘extremely bullish’, with message volume rising 47% over the past 24 hours. Activity on the platform has also surged more than 1,000% over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_dd7c4a4253.webp" alt="sls ss.png" width="974" height="141"><figcaption>SLS sentiment and message volume as of March 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/yG19/message/646454150">said</a>, “Just a reminder that there are 99.99% chances of success for REGAL. Failure is a statistical impossibility.”<stembedurl>https://stocktwits.com/yG19/message/646454150</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Shawhwk/message/646510675">noted</a>, “Nice steady climb on decent volume. A PR Friday morning would be epic.”<stembedurl>https://stocktwits.com/Shawhwk/message/646510675</stembedurl>SLS stock has risen 41% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has risen 41% year-to-date. (Photo credit: Getty Images)

SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside

The rally comes ahead of results from the Phase 3 Regal trial testing Galinpepimut-S (GPS) as a maintenance treatment for AML patients.

SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High - Time to Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 1-Year High - Here's What Happened...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heightened cash reserves from recent warrant exercises and a notable period of management silence point towards active preparations for a potential acquisition, fueling investor excitement.

Recent warrant exercises have injected over $42.6M into the company's balance sheet, now estimated above $100M cash, which is seen as removing dilution concerns and strengthening financial leverage.

The extended timeline for the REGAL Phase 3 trial to accrue 80 events is widely interpreted as a positive sign that patients in the study are living significantly longer.

With an approximate 49M shares shorted and decreasing warrant-based hedges, many anticipate an impending short squeeze as major catalysts near, potentially driving a price surge.

Anticipation builds for advancements and potential accelerated FDA approval for the SLS009 program, especially with new frontline AML cohorts expected to initiate soon.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc